SCHEMBL19987440

SCHEMBL19987440

CCCCC(=O)Nc1cc(C)on1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.64
EGFR P00533 2/20 0.64
GAA P10253 2/20 0.64
MAPT P10636 1/20 0.60
PKM P14618 1/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
HSD17B10 Q99714 2/20 0.57
TP53 P04637 1/20 0.57
ALOX15 P16050 1/20 0.57
MAPK1 P28482 1/20 0.57
CASP1 P29466 1/20 0.57
CASP7 P55210 1/20 0.57
LMNA P02545 1/20 0.57
GAPDH P04406 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HTT P42858 1/20 0.56
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4112089 0.90 ALDH1A1 (0.68) ALDH1A1EGFRGAAMAPTPKM
SCHEMBL5849633 0.86 ALDH1A1 (0.67) ALDH1A1EGFRGAAMAPTPKM
SCHEMBL4110225 0.83 ALDH1A1 (0.72) ALDH1A1EGFRGAAMAPTHSD17B10
SCHEMBL1302998 0.82 ALDH1A1 (0.66) ALDH1A1EGFRGAAMAPTPKM
SCHEMBL4858124 0.82 ALDH1A1 (0.66) ALDH1A1EGFRGAAMAPTPKM
Iodide SCHEMBL3086980 0.81 ALDH1A1 (0.64) ALDH1A1EGFRGAAMAPTPKM
Hydrochloric Acid SCHEMBL3086707 0.81 ALDH1A1 (0.64) ALDH1A1EGFRGAAMAPTPKM
SCHEMBL11395044 0.80 EGFR (0.67) EGFRMAPTPKMLMNASMN1; SMN2
SCHEMBL11646187 0.79 NPC1 (0.50) ALDH1A1EGFRGAAMAPTCYP1A2
SCHEMBL2639258 0.78 ALDH1A1 (0.70) ALDH1A1EGFRGAAMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10399932-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2019-09-03 US disclosed
US-20180079712-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10399932-B2 Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer IDO1, IDO2, INMT ALDH1A1 263/4885EGFR 1090/4885GAA 480/4885
US-20180079712-A1 INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT ALDH1A1 263/4885EGFR 1090/4885GAA 480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.